M. Deschauer, MD

S. Tennant, DipRCPath

A. Rokicka, MD

L. He, PhD

T. Kraya, MD

D.M. Turnbull, FRCP

S. Zierz, MD

R.W. Taylor, PhD

**Supplemental data**

**at** [**www.neurology.org**](http://www.neurology.org/)

**MELAS ASSOCIATED WITH MUTATIONS IN THE**

***POLG1* GENE**

MELAS (mitochondrial myopathy, encephalopa­ thy, lactic acidosis, and strokelike episodes) syn­ drome is a characteristic mitochondrial disorder caused by point mutations in the mitochondrial ge­ nome (mtDNA).1 In addition to primary mtDNA defects, mutations in nuclear genes essential for mtDNA maintenance are emerging as important causes of mitochondrial disease leading to second­ ary mtDNA changes including mtDNA depletion and multiple mtDNA deletions. Of particular inter­ est are mutations in the mtDNA polymerase ')' *(POLGl)* gene, which are associated with a pheno­ typic spectrum ranging from Alpers syndrome to re­ cessive ataxia and late-onset progressive external ophthalmoplegia (PEO).2•5 We describe a patient with strokelike episodes typical of MELAS due to mutation of *POLGl.*

Case history. A 28-year-old man was admitted to hospital at age 23 years because of acute onset of head jerking to the left side and vomiting, preceded by several days of visual scintillations and right­ sided headache. He had been well until 2 years pre­ viously when it was noted that he had problems with coordination and concentration. Neurologic examination revealed left homonymous hemi­ anopia, areflexia, and sensory ataxia. A few hours after admission, he developed left-sided focal sei­ zures with secondary generalization leading to sta­ tus epilepticus, which was successfully treated with clonazepam and valproate. Cognitive deficits in memory and attention were noted, and there was a degree of motor apraxia. Over the past 5 years, there have been no further strokelike-episodes or seizures. Neurologic examination reveals left-sided homonymous hemianopia, a **mild** cognitive deficit, areflexia, and sensory ataxia but no ophthalmople­ gia. There is no family history of note.

Laboratory investigations, including measure­

ments of blood lactate, liver enzymes, and creatine kinase, were unremarkable. Examination of CSF showed a mild increase in protein (62.1 mg/dL, nor­ mal <50 mg/dL) and elevated lactate (3.4 mmol/L, normal <2.1 mmol/L). Brain MRI revealed a right­ sided occipital lesion (figure, A). EEG showed focal sharp waves in the right occipital region. Neuro­ physiology and sural nerve biopsy revealed a sen­ sory axonal peripheral neuropathy. Examination of a muscle biopsy specimen demonstrated subsar­ colemmal accumulation of mitochondria in some fi­ bers, with enzyme histochemistry revealing 5% cytochrome *c* oxidase (COX)-deficient fibers but no strongly succinate dehydrogenase (SDH)-posi-

tive vessels (figure, B). Respiratory chain complex activities were normal in muscle.

The 3243A>G, 3271T>C and 8344A>G

mtDNA mutations were not detected in muscle, and Southern blot analysis did not reveal evidence of mtDNA rearrangements. Long-range PCR, how­ ever, amplified several smaller bands compatible with multiple mtDNA deletions, which was con­ firmed by real-time PCR analysis of clonally expanded mtDNA deletions in individual cells (figure, C).6

Sequencing of the *ANTl* and *PEOl* genes re­ vealed no mutations, but analysis of *POLGl* re­ vealed two reported heterozygous missense mutations in compound c.l880G>A in exon 10 pre­ dicting R627Q and c.2542G>A in exon 16 predict­ ing G848S. Sequencing of parental samples confirmed recessive inheritance of the mutated al­ leles (figure E-1 on the *Neurology* Web site at [www.neurology.org).](http://www.neurology.org/)


**Discussion.** Our patient's clinical presentation (strokelike episode with occipital localization, headache, and seizures) and laboratory investiga­ tions (elevated CSF lactate, ragged-red fibers) fulfill the diagnostic criteria for MELAS. 1 The presence of COX-deficient fibers (although unusual in MELAS) and the absence of typical mtDNA point mutations prompted further investigations. Both long-range PCR and real-time PCR analyses detected multiple mtDNA deletions, confirming that low levels of multiple mtDNA deletions may sometimes remain undetected by Southern blot analysis3•4

Sequencing of the *POLGl* gene identified com­

pound heterozygous mutations, consistent with the negative family history and indicative of autosomal recessive inheritance. Both mutations have been re­ ported previously as recessive mutations, although not together; the R627Q mutation has been docu­ mented in patients with PEO and sensory ataxia, and Alpers syndrome, whereas the G848S mutation has been reported in patients with either PEO or Alpers syndrome ([http://dir-apps.niehs.nih.gov/polg/).](http://dir-apps.niehs.nih.gov/polg/))

Although *POLGl* mutations are widely de­ scribed in patients with encephalopathy, typical strokelike episodes are unusual, although there is a report of an ataxic patient with the A467T mutation whose 17-year-old sister had acute encephalopathy and seizures followed by cortical blindness and stu­ por, Cheyne-Stokes respiration, and sudden death.3 In other patients with *POLGl* mutations, cerebral lesions in the occipital lobes similar to MELAS were observed, but strokelike-episodes were not report­ ed.4•5 Many of these patients presented with epilepsy and headache typically observed during strokelike

Neurology 68 May 15. 2007 1741



**Figure** MRI, histochemistry, and PCR of the brain

**B C**


A

**;f'+�**

*From the Department of Neurology (M.D., A.R., T.K., S.Z.),*

*Martin-Luther-Universitdt Halle-Wittenberg, Halle/Saale, Ger­ many; Northern Regional Genetics Service (S.T.), Institute of*

�, **�**

**C: 0**

.,

.,

,**"**,**i**

.

**100**

**80**

*=*:*·*:*•"*.*:&*

*Human Genetics, Newcastle upon Tyne, UK; Mitochondrial Research Group (LH., D.M.T., R.W.T.), School of Neurol­ ogy, Neurobiology and Psychiatry, The Medical School, New­ castle University, Newcastle upon Tyne, UK.*

* ·

,.

�

...\_,. ,

�

�

d

\'-'***t.,***-***,.*** �-�

i'! **60**

�

**:ii**

••

**'l; 40**

*Supported by the Wellcome Trust and Newcastle upon Tyne Hospitals NHS Foundation Trust.*

� , ***1,***-***r***� **"i**

>

*Disclosure: The authors report no conflicts of interest.*

' - �' -. 1\_,


.!! **20** •

••

�

*Received September* 25, *2006. Accepted in final form January*

\��}:;/i/



(A) T2-weighted MRI of the brain demonstrating a right­ sided occipital hyperintense cortical lesion that spares deeper white matter and does not conform to a large arterial territory as typically seen in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes).(Bl Histochemical demonstration of combined cytochrome c oxidase (COX) and succinate dehydrogenase activities in the patient's muscle biopsy specimen, revealing COX­ deficient ragged-red fibers (shown by asterisk).(C) Single-fiber real-time PCR showing that the majority of fibers contain high levels of *MTN04* gene deletion, which confirms a diagnosis of multiple mtDNA deletions.

B. Wildemann, MD

G. Rudofsky, Jr., MD

B. Kress, MD

S. Jarius, MD

F. Konig,MD

V. Schwenger, MD

1742

**o�----**

**COX-deficient**

**muscle fibers**

episodes, but their lesions were small compared with the occipital hyperintensity seen in our patient. The majority of patients presenting with liver fail­ ure did so following valproate treatment of status epilepticus, and even though our patient was treated successfully with valproate without precipitating liver failure, valproate administration should be avoided in patients with *POLGl* mutations.

In addition to the strokelike episode, our patient had a sensory neuropathy but no evidence of ptosis or PEO. Neuropathy with sensory ataxia is typically observed in patients with *POLGl* mutations3•5 and, al­ though not a characteristic feature of MELAS, a signif­ icant proportion of patients with the 3243A>G mutation have clinical signs of neuropathy.7

In conclusion, our case highlights the complexity of the relationship between genotype and phenotype in mitochondrial disorders and broadens the strik­ ing phenotypic variability of *POLGl* mutations that now must also include MELAS, a classic mitochon­ drial syndrome.

**THE TUMOR NECROSIS FACTOR RECEPTOR­ ASSOCIATED PERIODIC SYNDROME, THE BRAIN, AND TUMOR NECROSIS FACTOR-a ANTAGONISTS**

Case report. The tumor necrosis factor (TNF) re­ ceptor-associated periodic syndrome (TRAPS) is an autosomally dominant inherited disorder resulting from mutations within the TNF receptor super fam­ ily lA gene *(TNFRSFlA),* which impair cleavage of p55 TNF receptors (TNFRl), decrease soluble TNFRl serum levels, and affect intracellular traf­ ficking of mutant proteins. 1 The associated unop­ posed *TNFa* signaling confers self-limited autoinflammation and may promote amyloidosis. Here, we provide clinical and histologic evidence that TRAPS may affect the CNS and has to be in­ cluded in the spectrum of autoimmune inflamma­ tory CNS disorders.

Neurology 68 May 15, 2007

29, *2007.*

*Address correspondence and reprint requests to Dr. Robert* W. *Taylor, Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, The Medical School, Newcastle U�iversity, Newcastle upon Tyne, NE2 4HH, UK;* [*r.w.taylor@ncl.ac.uk*](mailto:r.w.taylor@ncl.ac.uk)

Copyright © 2007 by AAN Enterprises, Inc.

1. Hirano M, Ricci E, Koenigsberger R, et al. MELAS: an original case and clinical criteria for diagnosis. Neuro­ muscul Disord 1992;2:125-135.
2. Di Mauro S, Davidzon G, Hirano M. A polymorphic poly­ merase. Brain 2006;129:1637-1639.
3. Van Goethem G, Luoma P, Rantamaki M, et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 2004;63:1251-1257.
4. Winrerthun S, Ferrari G, He L, et al. Aurosomal recessive mitochondrial ataxic syndrome due to mitochondrial poly­ merase gamma mutations. Neurology 2005;64:1204-1208.
5. Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129:1685-1692.
6. He LP, Chinnery PF, Durham SE, et al. Detection and quantification of mitochondrial DNA deletions in indi­ vidual cells by real-time PCR. Nucleic Acids Res 2002;30: e68.
7. Kaufmann P, Pascual JM, Anziska Y, et al. Nerve conduc­ tion abnormalities in patients with MELAS and the A3243G mutation. Arch Neural 2006;63:746-748.

Our patient was diagnosed with a C55A muta­ tion in exon 3 of the *TNFRSFlA* gene and had expe­ rienced recurrent attacks of fever, myalgias, arthralgias, and painful migratory rashes since childhood. At age 38 he developed brainstem and cerebellar symptoms from an extensively contrast­ enhancing lesion in the left cerebellar peduncle; acute disseminated encephalomyelitis (ADEM) or lymphoma was considered.2 However, brain biopsy revealed a T-cell-predominated inflammatory infil­ trate without evidence of demyelination (figure, A through D). Moreover, treatment with several courses of methylprednisolone was only transiently effective, and cranial MRI revealed striking persis­ tence of contrast enhancement in the left infratento· rial lesion 1 year after disease onset (figure, E and F). CSF analysis showed a mild lymphocytic pleocy­ tosis of 7 cells/ *µ,L* and repeatedly negative oligo-